A Phase 1 Study of HB-301 and HB-302 in People With Advanced Prostate Cancer

Share

Full Title

A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants with Metastatic Castration-Resistant Prostate Cancer

Purpose

Researchers want to find the best dose of the drugs HB-301 and HB-302 to use in people with advanced prostate cancer. The people in this study have metastatic castration-resistant prostate cancer. This means their cancer has spread outside the prostate. The cancer also keeps growing even after taking hormonal therapies.

HB-301 and HB-302 are cancer vaccines. They use a virus that is inactivated and enhances the immune system to fight the cancer.

HB-301 and HB-302 may train the immune system to detect and fight two proteins often found on prostate cancer cells. These proteins are called PAP and PSA. By boosting your immune system’s ability to fight against these proteins, HB-301 and HB-302 may help kill cancer cells. The treatment is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have metastatic castration-resistant prostate cancer that keeps growing even after a treatment like enzalutamide.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Susan Slovin’s office at 646-422-4470.

Protocol

23-181

Phase

Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT05553639